OmRx Oncology begins Phase II trial of oral PD-L1 inhibitor for NSCLC
The trial will evaluate the overall response rate, as well as safety and other secondary efficacy endpoints.
09 May 2025
09 May 2025
The trial will evaluate the overall response rate, as well as safety and other secondary efficacy endpoints.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.